Veligrotug

Accent Therapeutics has dosed the first patient in a Phase I/II trial of ATX-295, an oral KIF18A inhibitor targeting solid tumors, including high-grade serious ovarian cancer.

TEPEZZA, the first FDA-approved treatment for thyroid eye disease, generated $1.9 billion in sales for 2024, with $460 million in Q4 alone, addressing a critical unmet need for patients with limited treatment alternatives.

Linsitinib, an oral small molecule, significantly reduced proptosis in patients with active, moderate to severe thyroid eye disease (TED) in a Phase 2b/3 trial.

Viridian Therapeutics' veligrotug met all primary and secondary endpoints in the THRIVE-2 Phase 3 trial for chronic thyroid eye disease (TED).

Several companies are actively developing novel therapies for Graves' Disease, targeting mechanisms like IGF-1R and FcRn.